Donskov, F. ., Viggo Jensen, N. ., & Smidt-Hansen, T. (2018). A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. Acta Oncologica, 57(5), 589–594. https://doi.org/10.1080/0284186X.2018.1433324